newsLong-term Phase II study data of small molecule inhibitor UBX1325…
24 April 2023 | By Catherine Eckford (European Pharmaceutical Review)
Long-term Phase II study data of small molecule inhibitor UBX1325 delivered significant vision improvements in diabetic macular edema (DME).